Ann: ATL1102 Revised Plans accelerate reporting of unblinded data, page-284

Well well this is a very interesting report and an update on the big 4 collaboration and their findings


Mendell’s research suggested the T cell attack made the gene therapy ineffective. Bonnemann said scientists will monitor the five patients that took part in this new analysis to see if something similar happened.

Also

In addition to excluding at-risk patients, drugmaker trials will also now monitor patients for treatment-specific T cell responses, and use drugs to manage that alongside the gene therapy, according to Bonnemann.


Taken from our early results


ATL1102 may prevent T-cell migration, resulting in lower inflammation and slower DMD progression.


Why the hell we are not screaming our findings from the rooftops in the US on a roadshow seeking funds to carry on our original Ph3

I have absolutely no idea, im sorry i just font get it

I say yet again pepgen raised $150 mil for initial exploration onto DMD

Yet here we sit with the possible answer the big 4 are looking for the modulation of T cells  


https://www.biopharmadive.com/news/duchenne-gene-therapy-side-effect-sarepta-pfizer-solid/623901/